This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Winters, M. A.
Right arrow Articles by Merigan, T. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Winters, M. A.
Right arrow Articles by Merigan, T. C.

 Previous Article  |  Next Article 

J Virol, June 1998, p. 5303-5306, Vol. 72, No. 6
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Human Immunodeficiency Virus Type 1 Protease Genotypes and In Vitro Protease Inhibitor Susceptibilities of Isolates from Individuals Who Were Switched to Other Protease Inhibitors after Long-Term Saquinavir Treatment

Mark A. Winters,* Jonathan M. Schapiro, Jody Lawrence, and Thomas C. Merigan

Center for AIDS Research at Stanford, Stanford University, Stanford, California

Received 27 October 1997/Accepted 3 March 1998

An understanding of the mechanisms of virologic cross-resistance between human immunodeficiency virus type 1 protease inhibitors is important for the establishment of effective treatment strategies for patients who no longer respond to their initial protease inhibitor. Protease gene sequencing results from patients treated with saquinavir showed significant increases in the frequency of the G48V protease mutation in patients receiving higher doses of the drug. In addition, all six patients who developed the G48V mutation during saquinavir therapy developed the V82A mutation either on continued saquinavir or after a switch to nelfinavir or indinavir. In vitro susceptibility assays showed that all 13 isolates with reduced susceptibilities to two or more protease inhibitors had either the G48V or L90M mutation, along with an average of six other protease mutations. Reduced susceptibility to nelfinavir was found in 14 isolates, but only 1 possessed the D30N mutation. These results suggest that mutations selected in vivo by initial saquinavir therapy may provide more cross-resistance to the other protease inhibitors than has been previously reported.

* Corresponding author. Mailing address: Center for AIDS Research at Stanford, 300 Pasteur Dr., Room S146, Stanford, CA 94305. Phone: (650) 723-5715. Fax: (650) 725-2395. E-mail: mawint{at}stanford.edu.

J Virol, June 1998, p. 5303-5306, Vol. 72, No. 6
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., Perros, M. (2005). Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity. Antimicrob. Agents Chemother. 49: 4721-4732 [Abstract] [Full Text]  
  • Svicher, V., Ceccherini-Silberstein, F., Erba, F., Santoro, M., Gori, C., Bellocchi, M. C., Giannella, S., Trotta, M. P., Monforte, A. d., Antinori, A., Perno, C. F. (2005). Novel Human Immunodeficiency Virus Type 1 Protease Mutations Potentially Involved in Resistance to Protease Inhibitors. Antimicrob. Agents Chemother. 49: 2015-2025 [Abstract] [Full Text]  
  • Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T. Jr., Dewar, R. L., Metcalf, J. A., Hammer, S., Mellors, J. W., Coffin, J. M. (2005). Multiple, Linked Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Treatment-Experienced Patients Are Missed by Standard Genotype Analysis. J. Clin. Microbiol. 43: 406-413 [Abstract] [Full Text]  
  • Marcelin, A.-G., Dalban, C., Peytavin, G., Lamotte, C., Agher, R., Delaugerre, C., Wirden, M., Conan, F., Dantin, S., Katlama, C., Costagliola, D., Calvez, V. (2004). Clinically Relevant Interpretation of Genotype and Relationship to Plasma Drug Concentrations for Resistance to Saquinavir-Ritonavir in Human Immunodeficiency Virus Type 1 Protease Inhibitor-Experienced Patients. Antimicrob. Agents Chemother. 48: 4687-4692 [Abstract] [Full Text]  
  • Watkins, T., Resch, W., Irlbeck, D., Swanstrom, R. (2003). Selection of High-Level Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors. Antimicrob. Agents Chemother. 47: 759-769 [Abstract] [Full Text]  
  • Imamichi, T., Murphy, M. A., Adelsberger, J. W., Yang, J., Watkins, C. M., Berg, S. C., Baseler, M. W., Lempicki, R. A., Guo, J., Levin, J. G., Lane, H. C. (2002). Actinomycin D Induces High-Level Resistance to Thymidine Analogs in Replication of Human Immunodeficiency Virus Type 1 by Interfering with Host Cell Thymidine Kinase Expression. J. Virol. 77: 1011-1020 [Abstract] [Full Text]  
  • Shulman, N., Zolopa, A., Havlir, D., Hsu, A., Renz, C., Boller, S., Jiang, P., Rode, R., Gallant, J., Race, E., Kempf, D. J., Sun, E. (2002). Virtual Inhibitory Quotient Predicts Response to Ritonavir Boosting of Indinavir-Based Therapy in Human Immunodeficiency Virus-Infected Patients with Ongoing Viremia. Antimicrob. Agents Chemother. 46: 3907-3916 [Abstract] [Full Text]  
  • Aslanzadeh, J. (2002). HIV Resistance Testing: an Update. Annals of Clinical & Laboratory Science 32: 406-413 [Abstract] [Full Text]  
  • Grant, R. M., Hecht, F. M., Warmerdam, M., Liu, L., Liegler, T., Petropoulos, C. J., Hellmann, N. S., Chesney, M., Busch, M. P., Kahn, J. O. (2002). Time Trends in Primary HIV-1 Drug Resistance Among Recently Infected Persons. JAMA 288: 181-188 [Abstract] [Full Text]  
  • Shafer, R. W. (2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev. 15: 247-277 [Abstract] [Full Text]  
  • Beck, I. A., Mahalanabis, M., Pepper, G., Wright, A., Hamilton, S., Langston, E., Frenkel, L. M. (2002). Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors. J. Clin. Microbiol. 40: 1413-1419 [Abstract] [Full Text]  
  • Maguire, M., Shortino, D., Klein, A., Harris, W., Manohitharajah, V., Tisdale, M., Elston, R., Yeo, J., Randall, S., Xu, F., Parker, H., May, J., Snowden, W. (2002). Emergence of Resistance to Protease Inhibitor Amprenavir in Human Immunodeficiency Virus Type 1-Infected Patients: Selection of Four Alternative Viral Protease Genotypes and Influence of Viral Susceptibility to Coadministered Reverse Transcriptase Nucleoside Inhibitors. Antimicrob. Agents Chemother. 46: 731-738 [Abstract] [Full Text]  
  • Yoshimura, K., Kato, R., Kavlick, M. F., Nguyen, A., Maroun, V., Maeda, K., Hussain, K. A., Ghosh, A. K., Gulnik, S. V., Erickson, J. W., Mitsuya, H. (2002). A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site. J. Virol. 76: 1349-1358 [Abstract] [Full Text]  
  • Kim, E.-Y., Winters, M. A., Kagan, R. M., Merigan, T. C. (2001). Functional Correlates of Insertion Mutations in the Protease Gene of Human Immunodeficiency Virus Type 1 Isolates from Patients. J. Virol. 75: 11227-11233 [Abstract] [Full Text]  
  • Albrecht, M. A., Bosch, R. J., Hammer, S. M., Liou, S.-H., Kessler, H., Para, M. F., Eron, J., Valdez, H., Dehlinger, M., Katzenstein, D. A., the AIDS Clinical Trials Group 364 Study Team, (2001). Nelfinavir, Efavirenz, or Both after the Failure of Nucleoside Treatment of HIV Infection. NEJM 345: 398-407 [Abstract] [Full Text]  
  • La Seta Catamancio, S., De Pasquale, M. P., Citterio, P., Kurtagic, S., Galli, M., Rusconi, S. (2001). In Vitro Evolution of the Human Immunodeficiency Virus Type 1 Gag-Protease Region and Maintenance of Reverse Transcriptase Resistance following Prolonged Drug Exposure. J. Clin. Microbiol. 39: 1124-1129 [Abstract] [Full Text]  
  • Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C. (2001). Comparison of DNA Sequencing and a Line Probe Assay for Detection of Human Immunodeficiency Virus Type 1 Drug Resistance Mutations in Patients Failing Highly Active Antiretroviral Therapy. J. Clin. Microbiol. 39: 454-459 [Abstract] [Full Text]  
  • O'Meara, D., Wilbe, K., Leitner, T., Hejdeman, B., Albert, J., Lundeberg, J. (2001). Monitoring Resistance to Human Immunodeficiency Virus Type 1 Protease Inhibitors by Pyrosequencing. J. Clin. Microbiol. 39: 464-473 [Abstract] [Full Text]  
  • Schmidt, B., Korn, K., Moschik, B., Paatz, C., Überla, K., Walter, H. (2000). Low Level of Cross-Resistance to Amprenavir (141W94) in Samples from Patients Pretreated with Other Protease Inhibitors. Antimicrob. Agents Chemother. 44: 3213-3216 [Abstract] [Full Text]  
  • Mammano, F., Trouplin, V., Zennou, V., Clavel, F. (2000). Retracing the Evolutionary Pathways of Human Immunodeficiency Virus Type 1 Resistance to Protease Inhibitors: Virus Fitness in the Absence and in the Presence of Drug. J. Virol. 74: 8524-8531 [Abstract] [Full Text]  
  • Rusconi, S., La Seta Catamancio, S., Citterio, P., Kurtagic, S., Violin, M., Balotta, C., Moroni, M., Galli, M., d'Arminio-Monforte, A. (2000). Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors. Antimicrob. Agents Chemother. 44: 1328-1332 [Abstract] [Full Text]  
  • Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., Katzenstein, D., Merigan, T. C., Efron, B. (1999). HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed. ANN INTERN MED 131: 813-821 [Abstract] [Full Text]  
  • Olsen, D. B., Stahlhut, M. W., Rutkowski, C. A., Schock, H. B., vanOlden, A. L., Kuo, L. C. (1999). Non-active Site Changes Elicit Broad-based Cross-resistance of the HIV-1 Protease to Inhibitors. J. Biol. Chem. 274: 23699-23701 [Abstract] [Full Text]  
  • Palmer, S., Shafer, R. W., Merigan, T. C. (1999). Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates. Antimicrob. Agents Chemother. 43: 2046-2050 [Abstract] [Full Text]  
  • Dulioust, A., Paulous, S., Guillemot, L., Delavalle, A.-M., Boue, F., Clavel, F. (1999). Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors. J. Virol. 73: 850-854 [Abstract] [Full Text]  
  • Pratt, R. E., Dzau, V. J. (1999). Genomics and Hypertension : Concepts, Potentials, and Opportunities. Hypertension 33: 238-247 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»